David Maag
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Advanced Breast Cancer Therapies, Glioma Diagnosis and Treatment, Cancer Treatment and Pharmacology, RNA and protein synthesis mechanisms
Most-Cited Works
- → The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen(2000)812 cited
- → Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial(2018)750 cited
- → Inositol Pyrophosphates Inhibit Akt Signaling, Thereby Regulating Insulin Sensitivity and Weight Gain(2010)361 cited
- → The Eukaryotic Translation Initiation Factors eIF1 and eIF1A Induce an Open Conformation of the 40S Ribosome(2007)332 cited
- → Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial(2020)310 cited
- → Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin(2001)279 cited
- → Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors(2015)262 cited
- → Pi Release from eIF2, Not GTP Hydrolysis, Is the Step Controlled by Start-Site Selection during Eukaryotic Translation Initiation(2005)259 cited
- → PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow(2018)251 cited
- → The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex(2017)232 cited